koto_feja
- AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said that its late-stage study of Datroway (datopotamab deruxtecan), being evaluated as a first-line treatment for patients with triple-negative breast cancer, met main goals.
- The study demonstrated a significant and meaningful improvement in dual main